AKT1 and Splenomegaly: Treatment of one of the patients with rapamycin for over 6 years diminished splenomegaly and lymphadenopathy, suggesting aberrant activation of the AKT/mTORC1 pathway in vivo in humans in the absence of functional GIMAP5.